New FDA rule cracks down on compounded drug ingredients

Compounded medicine has a valuable place in health care. A pharmacist may turn a tablet into a liquid for a child, remove a dye that triggers an allergy, or prepare a patient-specific dose that is not commercially available. In those situations, compounding is less like running a drug factory and more like tailoring a suit: the standard version does not fit, so a trained professional makes a careful adjustment.

The trouble begins when “customized medication” becomes a convenient label for producing unapproved drugs from poorly supported ingredients, advertising them to large groups of consumers, or bypassing the safeguards applied to FDA-approved products. That is where the Food and Drug Administration’s rules governing bulk drug substances enter the picture, clipboard in hand and eyebrows raised.

The 2019 final rule established formal criteria for deciding which bulk substances may be used under Section 503A of the Federal Food, Drug, and Cosmetic Act. It initially approved six substances for the agency’s 503A Bulks List and rejected four others. More importantly, it created a repeatable evidence-based framework for future ingredient decisions.

What are compounded drugs?

Drug compounding is the process of combining, mixing, or altering ingredients to create a medication for a particular patient. A compounded drug might contain a different strength, dosage form, flavor, or inactive ingredient than a commercially manufactured product.

Compounded drugs are not the same as generic drugs. A generic medication must undergo FDA review and demonstrate that it meets applicable standards, including therapeutic equivalence to its reference product. A compounded medication does not receive individual FDA approval before it is dispensed. The agency does not routinely verify each compounded product’s safety, effectiveness, potency, stability, or manufacturing quality before it reaches a patient.

Section 503A pharmacies

Section 503A generally covers traditional patient-specific compounding performed by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician. To qualify for important exemptions from standard drug approval, labeling, and manufacturing requirements, the compounder must satisfy specific statutory conditions.

Among other things, a 503A drug is ordinarily prepared for an identified individual based on a valid prescription. A pharmacy cannot simply make industrial quantities of an imitation commercial product, launch a national advertising campaign, and declare that every customer is somehow receiving a bespoke medical masterpiece.

Section 503B outsourcing facilities

Section 503B applies to outsourcing facilities that voluntarily register with the FDA. These facilities may compound certain medications without first receiving patient-specific prescriptions, but they face federal registration, inspection, adverse-event reporting, product reporting, and current good manufacturing practice requirements.

The Drug Quality and Security Act of 2013 created the outsourcing-facility framework after serious weaknesses in the nation’s compounding oversight system became impossible to ignore. Section 503B has a separate bulks list and different rules, so the 2019 rule discussed in this article applies specifically to the 503A pathway.

What the FDA’s compounded drug ingredient rule changed

Section 503A limits the bulk drug substances that may be used to prepare compounded medications. An ingredient generally must follow one of three routes:

• It complies with an applicable United States Pharmacopeia or National Formulary monograph.
• It is a component of an FDA-approved drug when no applicable monograph exists.
• It appears on the FDA’s 503A Bulks List when it has neither an applicable monograph nor approved-drug status.

The final route is the one targeted by the 2019 rule. Before an otherwise unrecognized bulk ingredient earns a spot on the list, the FDA evaluates the evidence rather than relying on popularity, anecdotes, decades of informal use, or a marketing brochure decorated with molecules and very confident stock-photo doctors.

The four factors used to evaluate ingredients

The FDA established four major criteria for evaluating a nominated bulk drug substance:

1. Physical and chemical characterization: Regulators examine whether the substance can be reliably identified, characterized, tested, stored, and formulated.
2. Safety concerns: The agency considers toxicity, contamination risks, adverse events, dosing hazards, administration routes, impurities, and other patient-safety issues.
3. Evidence of effectiveness or lack of effectiveness: Available clinical evidence matters. A colorful history of testimonials is not a substitute for dependable data.
4. Historical use: The FDA reviews how the ingredient has been used in compounded products, which conditions it has been used to treat, and whether that history appears in credible medical literature.

These criteria do not turn the 503A review into a full new-drug approval process. Compounders are not automatically required to conduct the same development program demanded of a pharmaceutical manufacturer seeking approval for a new prescription drug. Nevertheless, the rule makes clear that evidence counts and that “people have used it for years” is not a regulatory invisibility cloak.

Which ingredients were allowed and rejected?

The FDA’s initial final rule added six bulk drug substances to the 503A Bulks List:

• Brilliant Blue G, also known as Coomassie Brilliant Blue G-250
• Cantharidin, for topical use only
• Diphenylcyclopropenone, for topical use only
• N-acetyl-D-glucosamine, for topical use only
• Squaric acid dibutyl ester, for topical use only
• Thymol iodide, for topical use only

The route restrictions are important. An ingredient permitted for topical use does not receive an all-access backstage pass to be swallowed, inhaled, or injected. Route of administration can radically change a substance’s risk profile.

The FDA evaluated but did not add four other substances:

• Oxitriptan, also known as 5-hydroxytryptophan or 5-HTP
• Piracetam
• Silver protein mild
• Tranilast

Products compounded from these rejected substances do not qualify for the statutory exemptions based on inclusion on the 503A Bulks List. That does not necessarily mean every imaginable medical use will trigger immediate enforcement. For example, the FDA later announced a narrow enforcement-discretion policy for oral oxitriptan compounded for patients with tetrahydrobiopterin deficiency under specified conditions. This illustrates an important regulatory principle: broad commercial use and a tightly defined exceptional medical need are not the same thing.

Why the FDA tightened oversight

Compounding can solve legitimate treatment problems, but it also carries risks that are less common in standardized commercial manufacturing. Errors may involve incorrect potency, microbial contamination, unstable formulations, unsuitable ingredients, labeling mistakes, or sterility failures. A product can contain too little active ingredient and fail to work, or too much and turn an ordinary dose into a pharmaceutical jump scare.

These concerns are not theoretical. The 2012 multistate fungal outbreak linked to contaminated steroid injections from the New England Compounding Center resulted in 753 reported cases across 20 states and 64 deaths. The outbreak exposed gaps between traditional pharmacy oversight and large-scale drug manufacturing, ultimately helping drive passage of the Drug Quality and Security Act.

Other incidents have involved extreme potency errors, contaminated ophthalmic products, serious reactions, loss of vision, and deaths. In one case investigated by the FDA, a patient reportedly experienced cardiac arrest and died following an infusion of compounded intravenous curcumin. The agency has also warned that cesium chloride presents major cardiac risks, including dangerous arrhythmias and potentially fatal outcomes.

Such cases do not prove that every compounded medication is unsafe. They demonstrate why patient-specific usefulness cannot excuse weak sourcing, poor sterile technique, unsupported ingredients, or casual dosing. A parachute is useful too, but most people still prefer that someone inspect it before the airplane door opens.

What the rule does not do

The FDA rule does not ban pharmacy compounding. It does not prevent a pharmacist from preparing a medically necessary liquid, allergy-free formulation, unusual dose, or other legitimate patient-specific product when federal and state requirements are met.

It also does not mean every bulk substance must appear on the 503A Bulks List. Ingredients covered by an applicable USP or NF monograph, as well as qualifying components of FDA-approved drugs, may have separate legal pathways. The list primarily matters when a compounder wants to begin with a bulk substance that lacks both types of recognition.

Nor does placement on the list amount to FDA approval of every formulation made with that ingredient. The final compounded product is still not an FDA-approved drug. Formulation design, concentration, route, sterility, packaging, storage, beyond-use dating, prescription validity, and the compounder’s practices all remain critical.

How the rule affects pharmacies and prescribers

Pharmacies need better ingredient documentation

Compounders must know exactly what they are purchasing and from whom. Bulk substances generally need a valid certificate of analysis and must come from an establishment registered with the FDA as required by law. A supplier’s website saying “premium pharmaceutical awesomeness” is not a certificate of analysis, even when the text is printed in an impressively scientific shade of blue.

Pharmacies also need systems for checking the regulatory status of each substance, verifying applicable monographs, documenting supplier qualifications, investigating deviations, and reassessing formulas when FDA policies change.

Prescribers need a patient-specific reason

Clinicians should be able to explain why an FDA-approved medication cannot meet the patient’s needs. A meaningful difference might involve an allergy, dosage form, strength, route, or another documented clinical issue. Lower price, fashionable branding, or the opportunity to add vitamin B12 to nearly everything may not establish the required patient-specific medical difference.

Patients deserve clearer explanations

A patient should be told when a medication is compounded and understand that it has not undergone FDA premarket review. The discussion should cover why compounding is being recommended, what ingredient is used, what alternatives are available, how the product should be stored, and which warning signs require medical attention.

The rule’s long reach: peptides and compounded GLP-1 drugs

The 2019 regulation was an early milestone rather than the end of the process. The FDA continues to evaluate nominated substances, update its policies, consult advisory experts, and use enforcement discretion while portions of the 503A and 503B lists are developed. As of 2026, the agency still describes this as an ongoing, rolling evaluation process.

The same core questions have become highly visible in the booming market for compounded semaglutide, tirzepatide, and other peptide products: Where did the active pharmaceutical ingredient come from? Was it manufactured under appropriate controls? Is the formulation lawful? Is the seller describing an unapproved compounded drug as though it were an approved generic equivalent?

In 2025, the FDA created an import-alert “green list” intended to distinguish GLP-1 ingredient manufacturers that appeared compliant with applicable manufacturing standards from unverified foreign sources whose shipments could be detained. The agency cited concerns involving dosing errors, unapproved salt forms, adverse events, and poor-quality imported active ingredients.

In 2026, the FDA warned dozens of telehealth companies over allegedly false or misleading promotion of compounded GLP-1 products. The agency has emphasized that marketers should not call a compounded drug an FDA-approved generic, claim that it is FDA-approved, or imply that it has been proven to deliver the same clinical results as an approved product.

These actions are not identical to the original 503A Bulks List rule, but they reflect the same regulatory philosophy: compounding should address real patient needs, not operate as an escape tunnel around drug approval and manufacturing standards.

What patients should ask before using a compounded medication

Patients do not need to become part-time pharmaceutical attorneys, but a few direct questions can reveal a great deal:

• Why is an FDA-approved medication unsuitable for me?
• What is the exact active ingredient and dosage form?
• Is the prescription being filled by a properly licensed pharmacy?
• Is the facility a traditional 503A pharmacy or an FDA-registered 503B outsourcing facility?
• Where was the bulk ingredient manufactured?
• What testing was performed for identity, strength, purity, and sterility?
• How should the product be shipped, refrigerated, or protected from light?
• What side effects, dosing errors, or quality problems should I report?

Patients using an injectable compounded product should pay special attention to damaged containers, particles, discoloration, leaks, unusual labeling, and temperature problems during shipping. The FDA has specifically warned against using injectable GLP-1 products that arrive warm when refrigeration is required.

Experience-based lessons from the compounding world

The following examples are composite scenarios based on recurring regulatory, clinical, pharmacy, and patient experiences. They are not descriptions of specific identifiable patients.

Experience 1: The child who genuinely needs customization

A pediatrician prescribes a medication that is commercially available only as a tablet. The patient is four years old, cannot swallow pills, and needs a carefully calculated dose based on body weight. A licensed pharmacist prepares a stable liquid using an appropriate ingredient, documents the formula, labels the storage requirements, and provides a calibrated oral syringe.

This is traditional compounding doing exactly what it is supposed to do. The pharmacist is solving a defined medical problem for an identified patient. The customized product is not promoted to thousands of families as a revolutionary children’s wellness syrup. Nobody adds three trendy peptides and a motivational quote to the label. The experience is deliberately boring, which is often an excellent quality in medication preparation.

Experience 2: The patient confused by online GLP-1 marketing

A patient sees an advertisement for a “generic” version of a well-known weight-loss injection. The website uses pictures resembling the branded product and says the treatment contains a “clinically proven ingredient.” Only after reading several pages of fine print does the patient learn that the medication is compounded and has not been FDA-approved.

The practical lesson is that ingredient familiarity does not prove product equivalence. Two products may be described using similar active-ingredient language yet differ in source material, formulation, concentration, container, stability testing, dosing instructions, and manufacturing controls. Patients should not have to conduct an archaeological excavation through website disclaimers to discover what they are buying.

Experience 3: The pharmacy compliance review

During an internal audit, a pharmacy discovers that an older formula uses a bulk ingredient whose regulatory status has changed. The clinical team may have used the formula for years without obvious complaints, but longevity alone does not settle whether the product remains eligible for Section 503A exemptions.

The pharmacy pauses production, checks the current bulks list, reviews applicable USP and NF monographs, contacts the supplier, evaluates prescriptions already in process, and informs prescribers of possible alternatives. It is inconvenient work. It is also considerably less inconvenient than a recall, warning letter, patient injury, or conversation beginning with, “Apparently our ingredient file has not been updated since fax machines were exciting.”

Experience 4: The rare-disease exception

A substance may be unsuitable for broad inclusion on the 503A Bulks List yet remain clinically important for a tiny patient population with no practical alternative. Oxitriptan provides a useful example. Although it was not added to the list, the FDA later described circumstances in which it generally did not intend to take action against certain patient-specific oral compounding for tetrahydrobiopterin deficiency.

This experience shows why responsible regulation needs both rules and carefully defined flexibility. An unrestricted market could expose large numbers of consumers to poorly supported products. A rigid system with no room for exceptional cases could leave rare-disease patients stranded. The difficult task is to preserve access without turning every commercial ambition into an alleged medical exception.

Experience 5: The ingredient is only one part of quality

A pharmacy may purchase an ingredient with acceptable documentation and still produce a dangerous medication through incorrect calculations, insufficient mixing, contaminated equipment, poor sterilization, or unsuitable storage. Conversely, a beautifully maintained cleanroom cannot rescue an ingredient with uncertain identity or serious toxicological concerns.

The real-world lesson is that compounded-drug safety is a chain. Prescriber judgment, ingredient sourcing, formula design, staff training, environmental controls, testing, labeling, shipping, patient education, and adverse-event reporting are all links. Regulators cannot protect patients by examining only the powder in the first container, and pharmacies cannot achieve quality by hanging a framed cleanroom certificate in the lobby.

Conclusion

The FDA’s 503A bulk ingredient rule did not eliminate compounding or declare war on personalized medicine. It established a defensible boundary between legitimate customization and the unsupported use of bulk substances that lack an applicable monograph, approved-drug history, or sufficient evidence for inclusion on the federal list.

For pharmacies, the rule means closer attention to ingredient status, supplier qualification, certificates of analysis, clinical evidence, and patient-specific documentation. For prescribers, it means explaining why a compounded product offers a meaningful medical benefit that an approved product cannot provide. For patients, it means asking questions before assuming that “custom-made,” “natural,” “generic,” or “clinically proven” are interchangeable terms.

Compounding remains essential when standard products cannot meet an individual patient’s needs. It becomes dangerous when customization is used as camouflage for mass production, speculative therapies, weak quality controls, or misleading marketing. The FDA’s message is straightforward: personalized medicine may be flexible, but the evidence cannot be optional.

Note: This article is for general educational purposes and does not provide medical or legal advice. Patients should discuss compounded medications with a licensed health professional and verify pharmacies through the appropriate state board of pharmacy.